4. >>Compliance

House Leaders Suggest FTC Crack Down On Pandemic-Spurred Price Gouging, Hoarding

 
• By Malcolm Spicer

The same day Judiciary Chairman Jerrold Nadler and Energy and Commerce Chairman Frank Pallone submit a letter to the FTC, the agency announced work and travel schedule changes it is making in response to the Covid-19 pandemic.

Concept of the impact and threat of the corona virus health crisis, protective hygienic masks out of stock in purposely blurred drugstore shelves

Leaders of the US House Judiciary and Energy and Commerce committees urge the Federal Trade Commission to stop consumer health product price-gouging and hoarding spurred by the coronavirus outbreak.

The same day that Judiciary Chairman Jerrold Nadler, NY, and Energy and Commerce Chairman Frank Pallone, NJ, submitted a letter...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Compliance

FDA Warns Whoop BPI App Is Unauthorized Device; Firm Says Wearable Is A Wellness Tool

 
• By Brian Bossetta

Recent FDA warning letter claims Boston firm specializing in wearable technology marketed a blood pressure device without agency approval, but the company rejects the assertion and says the agency is out of step with federal regulations.

Remote Regulatory Assessments Become Swiss Army Knife For US FDA’s Oversight Of Facilities

 
• By Malcolm Spicer

“RRAs are valuable oversight tools and under certain circumstances, can assist FDA in its mission to protect public health, oversee regulated industry, and help ensure regulated products comply with FDA requirements,” according to final guidance.

Paying User Fees Not A Priority For Many OTC Monograph Drug Firms, First Arrears List Shows

 
• By Malcolm Spicer

The 1,383 entries on OMUFA arrears list for facility registrations from FY2021 through FY2025 on FDA’s list exceeds its estimate of 1,134 entities subject to the fee for FY2025.

FDA Draft Guidance Waves Green Flag On Changing Color Additives For Drugs In US

 
• By Malcolm Spicer

In a nod to drug manufacturers’ potential interest in moving to natural alternatives for petroleum-based synthetic dyes the agency intends to remove from use, document explains process for asking for approval for “any dye, pigment, or other substance that can impart color to a food, drug, cosmetic,

More from Policy & Regulation